VentX trans-Activates p53 and p16ink4a to Regulate Cellular Senescence

被引:16
|
作者
Wu, Xiaoming [1 ]
Gao, Hong [1 ]
Ke, Weixiong [1 ]
Hager, Martin [3 ]
Xiao, Sheng [2 ]
Freeman, Michael R. [3 ]
Zhu, Zhenglun [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Div Gastroenterol, Sch Med,Dept Med, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA
[3] Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; STEM-CELLS; IN-VIVO; INDUCE SENESCENCE; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; CANCER-TREATMENT;
D O I
10.1074/jbc.M110.206078
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cell senescence is a process of irreversible arrest of cell proliferation and plays an important role in tumor suppression. Recent studies showed that Wnt inhibition is a trigger of cellular senescence. Using methods of reverse genetics, we recently identified VentX, a human homolog of the vertebrate Xenopus Vent family of homeobox genes, as a novel Wnt repressor and a putative tumor suppressor in lymphocytic leukemia. Here, we show that VentX is a direct transcriptional activator of p53-p21 and p16(ink4a)-Rb tumor suppression pathways. Ectopic expression of VentX in cancer cells caused an irreversible cell cycle arrest with a typical senescence-like phenotype. Conversely, inhibition of VentX expression by RNA interference ameliorated chemotherapeutic agent-induced senescence in lymphocytic leukemia cells. The results of our study further reveal the mechanisms underlying tumor suppression function of VentX and suggest a role of VentX as a potential target in cancer prevention and treatment.
引用
收藏
页码:12693 / 12701
页数:9
相关论文
共 50 条
  • [1] pRB, p53, p16INK4a senescence and malignant transformation
    Larsen, CJ
    [J]. BULLETIN DU CANCER, 2004, 91 (05) : 399 - 402
  • [2] p16INK4a in cellular senescence
    Simboeck, Elisabeth
    Di Croce, Luciano
    [J]. AGING-US, 2013, 5 (08): : 590 - 591
  • [3] A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy
    Hayward, RL
    Smyth, JF
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (17) : 2207 - 2209
  • [4] p16INK4a and p53 deficiency cooperate in tumorigenesis
    Sharpless, NE
    Alson, S
    Chan, S
    Silver, DP
    Castrillon, DH
    DePinho, RA
    [J]. CANCER RESEARCH, 2002, 62 (10) : 2761 - 2765
  • [5] A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy
    Schmitt, CA
    Fridman, JS
    Yang, M
    Lee, S
    Baranov, E
    Hoffman, RM
    Lowe, SW
    [J]. CELL, 2002, 109 (03) : 335 - 346
  • [6] p16Ink4a in melanocyte senescence and differentiation
    Sviderskaya, EV
    Hill, SP
    Evans-Whipp, TJ
    Chin, L
    Orlow, SJ
    Easty, DJ
    Cheong, SC
    Beach, D
    DePinho, RA
    Bennett, DC
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (06) : 446 - 454
  • [7] Regulation of p16INK4a, senescence and oncogenesis
    Chien, Wei Wen
    Ffrench, Martine
    [J]. M S-MEDECINE SCIENCES, 2006, 22 (10): : 865 - 871
  • [8] Characterization of a new independent senescence induction path in p53/p21CIP1 and p16INK4A
    Prieur, A.
    Besnard, E.
    Babled, A.
    Lemailre, J. -M.
    [J]. BULLETIN DU CANCER, 2011, 98 : S45 - S45
  • [9] p16INK4a is a prognostic marker in resected ductal pancreatic cancer -: An analysis of p16INK4a, p53, MDM2, an Rb
    Gerdes, B
    Ramaswamy, A
    Ziegler, A
    Lang, SA
    Kersting, M
    Baumann, R
    Wild, A
    Moll, R
    Rothmund, M
    Bartsch, DK
    [J]. ANNALS OF SURGERY, 2002, 235 (01) : 51 - 59
  • [10] p16INK4a modulates p53 in primary human mammary epithelial cells
    Zhang, Jianmin
    Pickering, Curtis R.
    Holst, Charles R.
    Gauthier, Mona L.
    Tlsty, Thea D.
    [J]. CANCER RESEARCH, 2006, 66 (21) : 10325 - 10331